Autres langues Cogent Biosciences, Inc.

Actions

COGT

US19240Q2012

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 25/09/2026			Varia. 5j.	Varia. 1 janv.
32,31 ^USD	+2,80%		+2,57%	-9,04%

15/09	Cogent Biosciences, Inc. annonce l'acceptation par la FDA de la demande de mise sur le marché du bezuclastinib pour les patients atteints de mastocytose systémique avancée	CI
15/09	Cogent Biosciences : la FDA accepte le dossier d'homologation du bezuclastinib dans la mastocytose systémique avancée	MT

Autres langues

15/09	Cogent Biosciences, Inc. Announces FDA Acceptance Of New Drug Application For Bezuclastinib In Patients With Advanced Systemic Mastocytosis
15/09	Cogent Biosciences Gets US FDA Acceptance for Bezuclastinib AdvSM Application
15/09	Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) for Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
02/09	Cogent Biosciences Enters Commercial Supply Agreement With Hovione FarmaCiencia
31/08	Cogent Biosciences Insider Sold Shares Worth $1,689,493, According to a Recent SEC Filing
10/08	Cogent Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
10/08	Cogent Biosciences Q2 Loss Widens
10/08	Earnings Flash (COGT) Cogent Biosciences Posts Q2 Net Loss $96.4M, vs. FactSet Est of $98M Loss
10/08	Cogent Biosciences : August 10, 2026
10/08	Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2026 Financial Results
30/06	Cogent Biosciences Submits New Drug Application for Bezuclastinib in Advanced Systemic Mastocytosis
30/06	Cogent Biosciences Submits US FDA New Drug Application for Potential Mast Cell Disease Treatment
30/06	Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM)
29/06	Cogent Biosciences, Inc.(NasdaqGS:COGT) dropped from Russell 2000 Value Benchmark
29/06	Cogent Biosciences, Inc.(NasdaqGS:COGT) dropped from Russell Microcap Value Benchmark Index
29/06	Cogent Biosciences, Inc.(NasdaqGS:COGT) dropped from Russell Microcap Growth Benchmark Index
29/06	Cogent Biosciences, Inc.(NasdaqGS:COGT) dropped from Russell 3000E Growth Benchmark
29/06	Cogent Biosciences, Inc.(NasdaqGS:COGT) dropped from Russell Microcap Index
29/06	Cogent Biosciences, Inc.(NasdaqGS:COGT) dropped from Russell 3000E Value Benchmark
29/06	Cogent Biosciences, Inc.(NasdaqGS:COGT) dropped from Russell 3000 Value Benchmark
29/06	Cogent Biosciences, Inc.(NasdaqGS:COGT) dropped from Russell 3000E Index
29/06	Cogent Biosciences, Inc.(NasdaqGS:COGT) dropped from Russell Small Cap Comp Value Benchmark
29/06	Cogent Biosciences, Inc.(NasdaqGS:COGT) dropped from Russell 2500 Value Benchmark
12/06	Cogent Biosciences' Potential Rare Blood Disease Treatment Meets Endpoints in Clinical Trial
12/06	Cogent Biosciences Announces Detailed Data from APEX Pivotal Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis at the 2026 European Hematology Association (EHA) Congress